Mvasi (Bevacizumab)

Bevacizumab, the active ingredient in Mvasi, is a monoclonal antibody presented as an intravenous solution for intravenous use. It treats various solid tumours including metastatic colorectal cancer, non‑small cell lung cancer, glioblastoma, renal cell carcinoma, ovarian cancer and cervical cancer in adult patients.

GNH USA supplies Mvasi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mvasi (bevacizumab) is used in oncology to inhibit angiogenesis in several solid tumours.

Metastatic colorectal cancer: improves progression‑free survival when combined with chemotherapy. Non‑small cell lung cancer: extends overall survival as part of first‑line regimens. Glioblastoma: used with radiotherapy and temozolomide to delay tumour growth. Renal cell carcinoma: enhances response rates in combination therapy. Ovarian cancer: added to platinum‑based chemotherapy to increase disease‑free intervals. Cervical cancer: combined with chemoradiation to improve treatment outcomes.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring. - Proteinuria: presence of protein in urine, often mild. - Fatigue: general tiredness during treatment. - Infusion‑related reactions: flushing, chills, or rash. - Bleeding: nosebleeds or minor bruising. - Wound‑healing complications: delayed postoperative recovery.

Serious or Rare Side Effects: - Arterial thromboembolism: risk of heart attack or stroke. - Gastrointestinal perforation: severe abdominal emergency. - Severe hemorrhage: life‑threatening bleeding events. - Posterior reversible encephalopathy syndrome: neurological symptoms. - Severe infusion reactions: anaphylaxis or bronchospasm. - Severe hypertension: hypertensive crisis requiring immediate care.

Before initiating therapy, clinicians should assess patient suitability and monitor for adverse events.

Blood pressure monitoring: check before each infusion and manage hypertension promptly. Proteinuria assessment: perform regular urine protein tests. Wound healing: postpone elective surgery until treatment is completed. Bleeding risk: avoid in patients with recent major hemorrhage. Pregnancy: contraindicated; avoid use during pregnancy and breastfeeding. Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Bevacizumab may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants: increased risk of severe bleeding. - Other VEGF pathway inhibitors: additive toxicity and hypertension. - Live vaccines: heightened infection risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate bleeding tendencies. - Antihypertensives: dose adjustments may be needed due to blood‑pressure changes. - Thyroid hormone replacement: monitor thyroid function as bevacizumab can affect hormone levels.